These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 6161403)
1. [Symptomatic treatment of Raynaud's phenomenon: reserpine, alpha-methyldopa, griseofulvin, guanethidine]. Zicot M Rev Med Liege; 1980 Oct; 35(19):652-4. PubMed ID: 6161403 [No Abstract] [Full Text] [Related]
2. Pharmacologic management of Raynaud's phenomenon. Day TW; Mendoza F South Med J; 1984 Sep; 77(9):1160-4. PubMed ID: 6385288 [TBL] [Abstract][Full Text] [Related]
3. Griseofulvin in Raynaud's phenomenon. Naidoo P Lancet; 1971 Nov; 2(7733):1090. PubMed ID: 4106930 [No Abstract] [Full Text] [Related]
4. A double-blind clinical trial of griseofulvin in patients with Raynaud's phenomenon. Sabri S; Higgins RF; Roberts VC; Cotton LT; Williams DI; Wilson LC Postgrad Med J; 1973 Sep; 49(575):641-3. PubMed ID: 4596620 [TBL] [Abstract][Full Text] [Related]
5. Griseofulvin in Raynaud's phenomenon. Allen BR Lancet; 1971 Oct; 2(7729):840-1. PubMed ID: 4106870 [No Abstract] [Full Text] [Related]
6. Griseofulvin in Raynaud's disease. Hasker WE Lancet; 1970 Nov; 2(7683):1136. PubMed ID: 4097937 [No Abstract] [Full Text] [Related]
7. [Griseofulvin administered for an indeterminate time in the therapy of systemic scleroderma and Raynaud's syndrome]. Giordano M; Capelli L; Ara M; Tirri G Reumatismo; 1971; 23(2):82-92. PubMed ID: 5146109 [No Abstract] [Full Text] [Related]
16. Suppression of Raynaud's phenomenon by methyldopa. Varadi DP; Lawrence AM Arch Intern Med; 1969 Jul; 124(1):13-8. PubMed ID: 5791479 [No Abstract] [Full Text] [Related]
17. [Pathophysiology and medical treatment of Raynaud's phenomena]. Adar R Harefuah; 1973 Feb; 84(4):227-8. PubMed ID: 4574182 [No Abstract] [Full Text] [Related]